MatthewIMilowskyMD

Genitourinary Oncology

Professor of Medicine, Vice Chief of Research, Section Chief, Genitourinary Oncology, Division of Oncology and Co-Director, Urologic Oncology Program, UNC Lineberger Comprehensive Cancer Center

Join to view full profile

Dr. Milowsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Milowsky's full profile

Already have an account?

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 984-974-0000

Fax+1 919-843-6949

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Tufts Medical CenterResidency, Internal Medicine, 1996 - 1999
State University of New York Downstate Medical Center College of MedicineClass of 1996

Certifications & Licensure

NC State Medical License 2011 - 2025
NY State Medical License 1999 - 2013
American Board of Internal Medicine Medical Oncology

Clinical Trials

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma Start of enrollment: 2008 Jul 01
Terminated
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer Start of enrollment: 2012 Jul 24
Completed
Not Applicable
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Start of enrollment: 2013 Jun 01
Active, not recruiting
Phase 2
Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Jan 23
Completed
Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer Start of enrollment: 2013 Oct 01
Terminated
Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy Start of enrollment: 2016 May 01
Active, not recruiting
Phase 2
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Start of enrollment: 2017 Aug 24
Active, not recruiting
Phase 2
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

114 citations
Intravesical rAd–IFNa/Syn3 for patients with high-grade, bacillus calmette-guerin–refractory or relapsed non–muscle-invasive bladder cancer: A phase II randomized study
Neal D. Shore, Stephen A. Boorjian, Daniel J. Canter, Kenneth Ogan, Lawrence Karsh
Journal of Clinical Oncology. 2017-10-20
64 citations
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.
Hikmat Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, Oscar Lin, Adriana Heguy
The Journal of Pathology. 2011-06-01
631 citations
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer, Katherine A. Hoadley, David D. Chism, Cheng Fan, Christopher J. Tiganelli
Proceedings of the National Academy of Sciences of the United States of America. 2014-02-25

Lectures

Cost-effectiveness of CHOP in treating DLBCL in Malawi.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Carolina Cancer Experts Available for InterviewsMay 19th, 2023
Genetic Analysis of the Most Common Type of Bladder Cancer Yields Guidance on Treatment OptionsNovember 18th, 2022
Testicular Cancer Mapped Genomically and EpigenomicallyJune 13th, 2018
Join now to see all